CenExel ACT (Formerly Anaheim Clinical Trials; LLC)
Anaheim, California, 92801, United States
Location status: Recruiting
Location contact
Peter Winkle, Site 0001
CONTACT
Recruiting
NCT Number: NCT07723118
A Study to Assess the Pharmacokinetics, Safety and Tolerability of Single-dose Adagrasib (BMS-986503) in Healthy Participants of Japanese Descent
The aim of this study is to assess the pharmacokinetics, safety and tolerability of single-dose Adagrasib (BMS-986503) in healthy participants of Japanese descent
Recruiting
Interested in participating?
Request InfoKey information
Conditions
Age range
18 year–60 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 1
Primary location
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Participants must be of Japanese descent (both biological parents of the participant are ethnically Japanese).
- Participants must be healthy adult without clinically significant deviation from normal in medical history, PE, 12-lead ECG, vital sign measurements, and clinical laboratory assessments as determined by the investigator.
- Participants must have Body mass index of 18.0 kg/m2 to 32.0 kg/m2.
- Participants must have Total body weight ≥ 50 kg.
Exclusion criteria
- Participants must not have significant history or clinical manifestation of any metabolic, allergic, dermatological, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the investigator.
- Other protocol defined Inclusion/Exclusion criteria apply.
Treatment and study plan
Adagrasib
DrugSpecified dose on specified days
Other names: BMS-986503, MRTX849
Primary outcomes
-
Maximum Observed Plasma Concentration (Cmax)
Time frame: Up to Day 7
-
Time of Maximum Observed Plasma Concentration
Time frame: Up to Day 7
-
Area Under the Plasma Concentration-time Curve from Time Zero Extrapolated to Infinite Time [AUC(INF)]
Time frame: Up to Day 7
-
Area Under the Plasma Concentration-time Curve from Time Zero to Time of Last Quantifiable Concentration [AUC(0-T)]
Time frame: Up to Day 7
-
Apparent Terminal Phase Half-life (T-HALF)
Time frame: Up to Day 7
-
Apparent Total Body Clearance (CLT/F)
Time frame: Up to Day 7
-
Volume of Distribution of Terminal Phase (Vz/F)
Time frame: Up to Day 7
Secondary outcomes
-
Number of Participants with Treatment Emergent Adverse Events (AEs)
Time frame: Up to Day 13
-
Number of Participants with Clinical Laboratory Test Abnormalities
Time frame: Up to Day 7
-
Number of Participants with Vital Sign Abnormalities
Time frame: Up to Day 7
-
Number of Participants with Physical Examination (PE) Abnormalities
Time frame: Up to Day 7
-
Number of Participants with 12-Lead Electrocardiogram (ECG) Abnormalities
Time frame: Up to Day 7
Study contacts
Contact information is provided by the study sponsor or research team.
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
CONTACT
First line of the email MUST contain NCT # and Site #.
CONTACT
Sponsors and collaborators
Lead sponsor
Mirati Therapeutics Inc.
Industry
Registry information
Official study title
A Phase 1, Single-dose, Open-label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Adagrasib (BMS-986503) in Healthy Participants of Japanese Descent
Important dates
- Study start
- 2026
- Primary completion
- 2026
- Study completion
- 2026
- First posted
- Jul 23, 2026
- Registry last updated
- Aug 24, 2026
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Recruiting
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Enicepatide in Generally Healthy Adult Chinese Participants
NCT07626515
Healthy Participants
Beijing, China
View Trial Details
Recruiting
Comparative PK Assessment Study of Casdatifan in Moderate Hepatically Impaired Participants Versus Matched Participants With Normal Hepatic Function
NCT07751250
Healthy Participants, Hepatic Impairment
San Antonio, Texas, United States
View Trial Details
Recruiting
Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)
NCT07539090
Healthy Participants
Saint Paul, Minnesota, United States
View Trial Details
Recruiting
A Study to Learn How Different Amounts of the Study Medicine Called PF-08103402 Are Tolerated and Act in the Body in Healthy Adults or Adults With Mild To-moderate Asthma
NCT07660731
Asthma, Bronchial Diseases
New Haven, Connecticut, United States
View Trial Details